Can I use an ADHD report for medication management with another provider?

A healthcare-provider report is written so another prescriber can continue your treatment

The $99 healthcare-provider report exists because prescribers who did not do the assessment need more than a one-page letter before they will manage a controlled medication. It is a clinician-to-clinician document: it sets out how the diagnosis was reached (a video assessment against DSM-5-TR criteria, following CADDRA-aligned practice), which symptom domains were present, what other conditions were screened for, and what treatment plan was agreed. If medication has already been started, the report records the class of medication, the dose history, the response and any side effects, and the vital signs that were checked along the way.

That is different from the $49 standard diagnosis letter, which confirms that a diagnosis was made and by whom. A letter is enough for many administrative uses, but most prescribers asked to take on medication management will want the fuller report. The two documents and their prices are listed on the pricing page, and the transfer of care page explains how the handoff itself is arranged.

Receiving prescribers look for six things before they take over medication

A prescriber deciding whether to manage your medication is asking one question: can I safely continue this treatment without redoing the assessment? The report answers that when it covers the following.

1. Who made the diagnosis and how. Name, designation and registration details of the assessing clinician, the criteria used (DSM-5-TR) and the tools used, so the new prescriber can see the diagnosis rests on a recognised method.
2. Current medication by class, dose and schedule. Stimulant medications and non-stimulant options are recorded with the exact product, strength and timing, because the new prescriber will be writing that prescription themselves.
3. What was tried before and why it changed. Titration steps, discontinuations and the reason for each. This stops the new prescriber repeating a step that already failed.
4. Monitoring done to date. Baseline and follow-up blood pressure, heart rate and weight, plus any cardiac or psychiatric history that was screened, since CADDRA guidance expects these checks during stimulant treatment.
5. Coexisting conditions and risks. Screening results for mood, anxiety, sleep and substance use, and any history that affects prescribing decisions.
6. The plan. Recommended follow-up interval, what to watch for, and the circumstances in which the assessing clinician would want to be contacted.

The report does not transfer your prescriptions; the new provider writes new ones

A report is a clinical record, not a prescription. Stimulant medications used for ADHD are controlled substances under the federal Controlled Drugs and Substances Act, and the rules that govern them decide what happens to an existing prescription when you change prescribers. Two points matter in practice.

First, the prescription you already have keeps working until its authorised quantity is used up. In Ontario, the Ontario College of Pharmacists explains that a prescription for a controlled drug can be refilled only if the prescriber indicated the number of refills and the dates or intervals between them when it was written, and that a prescription for a narcotic cannot be refilled at all, only part-filled from the original quantity. Other provinces apply the same federal regulations through their own pharmacy regulators. So a new prescriber cannot simply add refills to a prescription written by someone else; they issue their own.

Second, if you also change pharmacies, the pharmacist can move an active controlled-substance prescription for you. The Ontario College of Pharmacists notes that pharmacist-to-pharmacist transfers of controlled substance prescriptions are permitted under a subsection 56(1) class exemption issued by Health Canada, and that once transferred the prescription becomes inactive at the original pharmacy. A prescription with no refills or quantity remaining cannot be transferred, though a copy can be provided for the new prescriber's records.

The practical sequence is therefore: share the report, have the new prescriber review it and see you, and let them write a fresh prescription that replaces the old one. Confirm the timing with both prescribers so that you do not run out between the last fill on the old prescription and the first fill on the new one.

Medication management can be shared, transferred outright, or bridged for a short period

The report supports three different arrangements, and it helps to tell both clinicians which one you want.

With shared care, ongoing follow-up with Finding Focus continues on the usual terms: the optional membership at $29.99 per month for adults, or $74.99 per check-in without membership. With a full transfer, those costs stop once the new prescriber has taken over. Which option suits you also depends on whether the other provider is willing, which is covered on the family doctor transfer page.

The report cannot oblige another clinician to prescribe, and it cannot solve a supply problem

Every prescriber decides independently whether to take on a patient's medication, and a report from any clinic, including Finding Focus, cannot compel that decision. Some family physicians prefer not to manage controlled medications; some will accept the report but ask to see you first; some will ask for a specific piece of information that the report did not include. If that happens, the clinic can usually add the missing detail or the assessing clinician can speak with the new prescriber directly. The transfer of care page explains what happens if a provider declines.

The report also cannot help with a shortage of a particular product. When a formulation is unavailable, the prescriber managing your medication decides whether to substitute a different strength or a different product in the same class, and the pharmacist confirms what is actually in stock. Health Canada publishes consumer-facing drug supply notices for active and resolved shortages, and its Drug Product Database lists every authorised product and its monograph, which is where a new prescriber checks alternatives. Neither the report nor Finding Focus can guarantee availability of any product.

Finally, the report reflects the assessing clinician's findings at the time it was written. A new prescriber is entitled to reach a different clinical judgment after seeing you, and an assessment can also conclude that a person does not have ADHD. If you are in crisis or thinking about harming yourself, call or text 9-8-8 or call 911 rather than waiting for any paperwork.